300+ investors in your industry, stage, and region Get
Any industry
Video Games
Hospitality
EdTech
Restaurants
Google
Construction
Photography
Clean Energy
CleanTech
Big Data
Email
Artificial Intelligence
Social Impact
SaaS
Energy
Mobile
Consumer
Health Care
Enterprise Software
Local
Platforms
Travel
InsurTech
Cryptocurrency
Oil and Gas
Payments
Retail
Film
Marketplace
Organic Food
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
Facebook
Social Network
Blockchain
B2B
Medical Device
Education
Wellness
Sports
Automotive
eSports
Legal
Biotechnology
Software
Renewable Energy
Crowdfunding
Recruiting
Web3
Medical
Theatre
Venture Capital
Social
Infrastructure
Beauty
Fashion
Climate
Life Science
Food and Beverage
Publishing
Mobile Apps
LGBT
Wine and Spirits
Music
Art
Cannabis
Real Estate
Sporting Goods
Manufacturing
Celebrity
FinTech
Finance
Digital Media
Social Media
Franchise
Financial Services
Non Profit
Android
Internet
Mobile Advertising
Proptech
Impact
Sustainability
Enterprise
Hardware
Biotech
Transportation
Community
Media (Entertainment)
Any country
Afghanistan
Greece
United Kingdom
Thailand
United Arab Emirates
Andorra
Benin
South Korea
Japan
Burkina Faso
Africa
Singapore
Brazil
LATAM
Gibraltar
Egypt
Taiwan
Zimbabwe
Hong Kong
Tunisia
Sweden
Nigeria
Togo
Croatia
Oceania
Iran
Guinea
Haiti
Kyrgyzstan
Norway
Lesotho
Isle of Man
Liberia
Malawi
Nepal
Mexico
Madagascar
Sudan
Russian Federation
Tajikistan
Pakistan
Zambia
Romania
Poland
Oman
Puerto Rico
Cameroon
Guernsey
Colombia
China
Armenia
Costa Rica
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
Australia
New Zealand
Morocco
Saudi Arabia
Sri Lanka
Jamaica
Guatemala
Switzerland
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Turkey
Uruguay
Seychelles
Moldova
Paraguay
Canada
Botswana
South Africa
France
Denmark
Georgia
Ireland
Ghana
Iraq
Latvia
Mali
Malaysia
Philippines
Rwanda
Portugal
El Salvador
Senegal
Tanzania
Sierra Leone
United States
India
Germany
Indonesia
Middle East
Dominican Republic
Bermuda
Albania
Asia
Argentina
Spain
Europe
Qatar
Angola
Cyprus
Barbados
Belgium
Jordan
Bangladesh
Ethiopia
Austria
Azerbaijan
Bulgaria
Ecuador
Faroe Islands
Jersey
Bolivia
Bahrain
Belize
Algeria
Italy
Estonia
Belarus
Finland
Hungary
Bahamas
Grenada
Israel
Lithuania
Honduras
Iceland
Cambodia
Lebanon
Liechtenstein
Mongolia
Slovenia
Peru
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
Cascara Ventures, VC Fund

Cascara Ventures

VC Fund

Brussels, Belgium

Cascara Ventures is a VC fund in Brussels focused on Health Care and Biotechnology. Cascara Ventures is the new investment fund of Adriaan Hart de Ruijter, experienced entrepreneur and investor in life sciences. Founded in 2016, Cascara invests in the seed stage of companies that apply technology to prevention, therapy and research. Examples are vaccines, medical devices, pharmaceuticals, imaging, software, medical data, robotics,healthcare services, diagnostics and cell therapy.

Total investments:
13
Last investment:
Lead investor:
8%

Last updated:

Industries Cascara Ventures invests in

Health CareBiotechnologyMedical DeviceMedicalWearables

Stages Cascara Ventures invests in

Series ASeedSeries BSeries CVenture - Series Unknown

Countries Cascara Ventures invests in

GermanyFinlandThe Netherlands

Round sizes

Series A $2M–$7.9M

Contacts

NameEmailPhoneSocials

Sign up to unlock verified contacts

Unlock Contacts

Round size

Series A
$2M–$7.9M

Investment Focus

Industry

  • Health Care 5 (38%)
  • Biotechnology 5 (38%)
  • Medical Device 5 (38%)
  • Medical 4 (31%)
  • Wearables 2 (15%)
See all 19 industries →

Stage

  • Series A 6 (46%)
  • Seed 3 (23%)
  • Series B 2 (15%)
  • Series C 1 (8%)
  • Venture - Series Unknown 1 (8%)

Country

  • Germany 6 (46%)
  • Finland 2 (15%)
  • The Netherlands 1 (8%)

Team

NameTitleInvestmentsLinksEmail
Adriaan Hart de Ruijter
Adriaan Hart de Ruijter Managing Director
Managing Director Total investments: 10
Find email

Investments

CompanyDescriptionRoundLinks
Surgify are currently preparing the commercialization of a novel technology for bone surgery at Aalto University with financial support from Tekes (Finnish Funding Agency for Innovation). To enable continuous communication with clinicians, they have been working in close cooperation with Neurosurgical Department of Helsinki University CentralHospital, part of HUS (The Hospital District of Helsinki and Uusimaa). $7.9M / Series A / May 27, 2025
ATRO Medical is a spin-out from DSM and Radboudumc and builds on the knowledge developed in the Public-Private Collaboration BioMedical Materials that started in 2010 with a consortium of universities, private companies, and financial support from the Dutch government. The collaboration between the clinical, biomechanical, and polymer expertise hascreated the base for the Trammpolin design and the development towards a prototype. $2.1M / Venture - Series Unknown / Dec 14, 2021
Surgify are currently preparing the commercialization of a novel technology for bone surgery at Aalto University with financial support from Tekes (Finnish Funding Agency for Innovation). To enable continuous communication with clinicians, they have been working in close cooperation with Neurosurgical Department of Helsinki University CentralHospital, part of HUS (The Hospital District of Helsinki and Uusimaa). $1.2M / Seed / Oct 25, 2017
ATRO Medical is a spin-out from DSM and Radboudumc and builds on the knowledge developed in the Public-Private Collaboration BioMedical Materials that started in 2010 with a consortium of universities, private companies, and financial support from the Dutch government. The collaboration between the clinical, biomechanical, and polymer expertise hascreated the base for the Trammpolin design and the development towards a prototype. Series A / Jul 17, 2017
Desentum is a research-oriented biopharmaceutical company specialized in developing novel types of allergy vaccines that are based on switching the immune system's response to allergens from hypersensitivity to tolerance. They have a unique approach for designing allergy vaccines. By studying the molecular mechanism of the hypersensitivityreaction, they have made discoveries that allow for improved design of vaccines against common types of allergies. Their goal is to provide long-term relief for patients suffering from allergic symptoms, as well as reduce the social and economic burden allergies cause to both individuals and society. $2M / Series A / Jan 23, 2017
microDimensions produces innovative software solutions for the processing, analysis, and visualization of biomedical imagery, in particular on a cellular level. Employees of microDimensions continuously strive to create efficient algorithms fulfilling highest quality standards. A particular focus of the company is to offer software products thatcan be integrated into the existing customer workflow seamlessly. Series A / Jun 16, 2016
xbird is a provider of software solutions in the healthcare sector, founded in Berlin in 2015. The company uses artificial intelligence to personalize therapies for better results. Especially in diabetes therapy, the algorithms developed by xbird can record the behavior and lifestyle of patients using smartphones and other wearables. In this way,as part of holistic care, health risks can be identified and prevented and long-term treatment can be optimized. Seed / Jan 01, 2016
Preventicus engineers products for smartphones and smartwatches that obtain health parameters without any extra accessories. It generates data conclusive to a degree previously only obtainable by physicians. Preventicus’ software applications are certified medical devices with an accuracy verified in clinical studies. Its primary product is a classI medical device. Preventicus is the creator of Preventicus Heartbeats, a smart screening solution that identifies atrial fibrillation for stroke prevention, based on technologies that are present in a standard smartphone or smartwatch.Preventicus was founded in 2014 by Thomas Hübner. It is based in Jena, Germany. Series A / Jan 01, 2016
Fiagon develops clinical navigation systems that reimagine image guidance by improving the function of electromagnetic navigation. Fiagon's systems use electromagnetic tracking matrix algorithms and flexible pointer technology that indicates the position of the instrument used in the CT or MRI image data, allowing physicians to get accurateplanning, improve patient outcomes, and implementation of the operation. Series C / Dec 31, 2015
microDimensions produces innovative software solutions for the processing, analysis, and visualization of biomedical imagery, in particular on a cellular level. Employees of microDimensions continuously strive to create efficient algorithms fulfilling highest quality standards. A particular focus of the company is to offer software products thatcan be integrated into the existing customer workflow seamlessly. Seed / Feb 27, 2014
See all 13 investments →

Co-Investors

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
Video Games
Hospitality
EdTech
Restaurants
Google
Construction
Photography
Clean Energy
CleanTech
Big Data
Email
Artificial Intelligence
Social Impact
SaaS
Energy
Mobile
Consumer
Health Care
Enterprise Software
Local
Platforms
Travel
InsurTech
Cryptocurrency
Oil and Gas
Payments
Retail
Film
Marketplace
Organic Food
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
Facebook
Social Network
Blockchain
B2B
Medical Device
Education
Wellness
Sports
Automotive
eSports
Legal
Biotechnology
Software
Renewable Energy
Crowdfunding
Recruiting
Web3
Medical
Theatre
Venture Capital
Social
Infrastructure
Beauty
Fashion
Climate
Life Science
Food and Beverage
Publishing
Mobile Apps
LGBT
Wine and Spirits
Music
Art
Cannabis
Real Estate
Sporting Goods
Manufacturing
Celebrity
FinTech
Finance
Digital Media
Social Media
Franchise
Financial Services
Non Profit
Android
Internet
Mobile Advertising
Proptech
Impact
Sustainability
Enterprise
Hardware
Biotech
Transportation
Community
Media (Entertainment)
Any country
Afghanistan
Greece
United Kingdom
Thailand
United Arab Emirates
Andorra
Benin
South Korea
Japan
Burkina Faso
Africa
Singapore
Brazil
LATAM
Gibraltar
Egypt
Taiwan
Zimbabwe
Hong Kong
Tunisia
Sweden
Nigeria
Togo
Croatia
Oceania
Iran
Guinea
Haiti
Kyrgyzstan
Norway
Lesotho
Isle of Man
Liberia
Malawi
Nepal
Mexico
Madagascar
Sudan
Russian Federation
Tajikistan
Pakistan
Zambia
Romania
Poland
Oman
Puerto Rico
Cameroon
Guernsey
Colombia
China
Armenia
Costa Rica
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
Australia
New Zealand
Morocco
Saudi Arabia
Sri Lanka
Jamaica
Guatemala
Switzerland
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Turkey
Uruguay
Seychelles
Moldova
Paraguay
Canada
Botswana
South Africa
France
Denmark
Georgia
Ireland
Ghana
Iraq
Latvia
Mali
Malaysia
Philippines
Rwanda
Portugal
El Salvador
Senegal
Tanzania
Sierra Leone
United States
India
Germany
Indonesia
Middle East
Dominican Republic
Bermuda
Albania
Asia
Argentina
Spain
Europe
Qatar
Angola
Cyprus
Barbados
Belgium
Jordan
Bangladesh
Ethiopia
Austria
Azerbaijan
Bulgaria
Ecuador
Faroe Islands
Jersey
Bolivia
Bahrain
Belize
Algeria
Italy
Estonia
Belarus
Finland
Hungary
Bahamas
Grenada
Israel
Lithuania
Honduras
Iceland
Cambodia
Lebanon
Liechtenstein
Mongolia
Slovenia
Peru
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does Cascara Ventures invest in?

Cascara Ventures invests primarily in Health Care, Biotechnology and Medical Device startups, most often at Series A and Seed stage. Most of the 13 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.

What is Cascara Ventures's check size?

Cascara Ventures typically joins rounds of $2M–$7.9M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Cascara Ventures participates in.

How do I contact Cascara Ventures?

Public channels for Cascara Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

Who are the partners at Cascara Ventures?

The team at Cascara Ventures includes Adriaan Hart de Ruijter (Managing Director). The Team section lists each member with their title, investment count and links.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
Cascara Ventures Cascara Ventures Find emails